Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q5JTJ3
UPID:
COA6_HUMAN
Alternative names:
-
Alternative UPACC:
Q5JTJ3; Q5JTJ2; Q5JTJ4; Q8TA88
Background:
Cytochrome c oxidase assembly factor 6 homolog plays a crucial role in the maturation of mitochondrial respiratory chain complex IV subunit MT-CO2/COX2. It is essential for the early steps of complex IV assembly, contributing to electron transfer and mitochondrial ATP synthesis. This protein also supports the formation of respiratory supercomplexes, enhancing cellular energy production.
Therapeutic significance:
The protein is linked to Mitochondrial complex IV deficiency, nuclear type 13, a severe infantile disorder with symptoms like hypertrophic cardiomyopathy and lactic acidosis. Understanding the role of Cytochrome c oxidase assembly factor 6 homolog could open doors to potential therapeutic strategies for this fatal condition.